Skip to Content

What is the difference between Renflexis and Remicade?

Medically reviewed by Last updated on Sep 16, 2019.

Official Answer


Renflexis (infliximab-abda) is a tumor necrosis factor (TNF) blocker that is biosimilar to Remicade (infliximab).

According to the FDA, a biosimilar must be shown to have no clinically meaningful differences in terms of safety and effectiveness from the reference product -- in this case Remicade. Only minor differences in clinically inactive components are allowable in biosimilar products.

What Are Biosimilars? Top Facts You May Not Know

Renflexis is given as an intravenous infusion similar to Remicade, and is indicated for the same indications, specifically treatment of Crohn disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.

The first biosimilar to Remicade, Pfizer’s Inflectra (infliximab-dyyb) was approved by the FDA in April, 2016.

For more information, see Comparing Remicade vs Renflexis

Related Medical Questions

Drug Information

Related Support Groups